Serotonin syndrome by drug interactions with linezolid: clues from pharmacovigilance-pharmacokinetic/pharmacodynamic analysis.

ABSTRACT:

Purpose

To characterize the post-marketing reporting of serotonin syndrome (SS) due to drug-drug interactions (DDIs) with linezolid and investigate the relationship with pharmacokinetic/pharmacodynamic (PK/PD) properties of serotonergic agents.

Methods

We queried the worldwide FDA Adverse Event Reporting System to extract SS records due to DDIs where linezolid was reported as suspect. For each serotonergic agent concomitantly reported, proportion of SS reports and mean number of DDIs were calculated and three different "SS reporting zones" were created. Relevant PK (peak concentration, area under plasma concentration curve, volume of distribution (V_D), and lipophilicity) and PD (values of binding affinity (Ki) and IC₅₀ for serotonin reuptake transporter

SUBMITTER: Gatti M 

PROVIDER: S-EPMC7803711 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature